Advancing DLBCL care and the role of bispecific antibodies - Dr. Martin Hutchings - Toronto
Dr. Martin Hutchings (Denmark), Dr. John Kuruvilla (Canada) | 77 minutes
Learning Objectives
- To discuss the evolving DLBCL treatment landscape
- To determine treatment considerations in 1L and R/R DLBCL
- To identify patient characteristics and considerations when evaluating CAR-T therapy and bispecifics
Disclaimer: This scientific meeting is sponsored by F. Hoffmann-La Roche Ltd.
This is a non-promotional meeting intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals within Canada. The content of this webinar may include scientific information about experimental or investigational compounds, indications, and services that are not approved by Health Canada.
The Evolving DLBCL Treatment Landscape
Pivotal CAR-T Trials in 3L+ DLBCL
Bispecific Antibodies
Prediction and Mitigation of CRS
Combination Studies
Q&A session